Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan

Initial findings from the EVAL study are expected to be released in Q4 2022

Study initiated to assess impact of Nociscan on the cost of care for chronic low back pain (CLBP) patients

Promising initial clinical evaluations with 87% of patients treated at discs identified as painful by Nociscan continuing to show significant clinical improvements at a two-year follow-up